Watch Pharma deals like Par Pharma / Endo --- MannKind will be like this one. Last week there was another deal just like this one with a company that doesn't even have an FDA approved product.
Every Pharma Deal has a happy ending and so does MannKind. Just this am a deal to acquire Par Pharm for 8 billion. Read the history of Par and you will see that MannKind is worth a Minimum of 15 Billion to Sanofi. Don't think that there is not an activist out there accumulating shares like What happened to Par in 2012.
The volatility of MannKind indicates that all the big players know that there blood in the water. So the HFT and Hedges know how the game is played and is playing it well. But the signs of the end game are there with the comments made at the B of A call the other day and watching the adaptation of users to the product. Sanofi will buy in to the company or be forced to do it by an activist to keep their stake from being impaired.
Something big will happen to MannKind. It will be the REGN or ALNY story as Sanofi partners well with their friends
TPG Bought Par Pharma for 1.9 Billion in 2012 and now sells it for 8.00 plus their debt. This again shows that MannKind will be an explosive deal when it happens. Mark my words it will happen SHORTLY.
. ---------------------------------------------------------------------------------------
Watch Pharma deals like Par Pharma / Endo --- MannKind will be like this one
Every Pharma Deal has a happy ending and so does MannKind. Just this am a deal to acquire Par Pharm for 8 billion. Read the history and you will see that MannKind is worth a Minimum of 15 Billion to Sanofi. Don't think that there is not an activist out there accumulating shares like What happened to Par in 2012. Something big will happen to MannKind. It will be the REGN or ALNY story as Sanofi partners well with their friends
TPG Bought Par Pharma for 1.9 Billion in 2012 and now sells it for 8.00 plus their debt. This again shows that MannKind will be an explosive deal when it happens. Mark my words it will happen SHORTLY.
. ---------------------------------------------------------------------------------------
Endo International said it would buy Par Pharmaceutical Holdings from private equity firm TPG Capital for about $8 billion, including debt.
"This is a transaction that's transformative for Endo in general, but specifically in generics, this will position us as a top-five generics player in the U.S.," Endo International CEO Rajiv De Silva said Monday on CNBC's "Squawk Box."
Par brings a diverse portfolio of existing products to Endo, as well as a product pipeline that is "arguably one of the best in the industry," the chief executive said. The deal will grow to "double digits" beginning in 2016, he added.
Dublin-based Endo's shares rose more than 1 percent in premarket trading Monday.
Endo said its offer consists of about 18 million shares and $6.5 billion in cash.
Par Pharmaceutical was acquired by TPG Capital for $1.9 billion in 2012 following pressure from activist firm Relational Investors LLC to sell itself.
The company, which filed with U.S. regulators in March for an initial public offering of common stock, had debt of $2.35 billion as of March 31.
